---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-343477"
form_type: "8-K"
ticker: "KLRS"
cik: "0001754068"
company_name: "Kalaris Therapeutics, Inc."
filed_at: "2026-08-11T12:05:28+00:00"
generated_at: "2026-08-11T12:10:41.490720+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Kalaris Q2 2026 net loss $11.5M; cash $93.5M funds operations into Q4 2027

## Summary
- Net loss $11.5M for Q2 2026 vs $11.4M in Q2 2025; R&D expense $9.0M (up from $8.4M).
- Cash, equivalents and marketable securities $93.5M as of June 30, 2026, down from $118.0M at Dec 31, 2025.
- Phase 1b/2 TH103 study dosing ongoing; preliminary data expected 1H 2027; Phase 3 start on track for year-end 2027.
- Expanded Phase 1a data released, reinforcing BCVA, OCT, pharmacokinetic and time-to-retreatment findings.
- Leadership additions: Liisa Bayko as CFO (from Evercore ISI) and Laurie Keating to Board of Directors.

## SEC filing metadata
- accession: 0001193125-26-343477
- form_type: 8-K
- ticker: KLRS
- cik: 0001754068
- company_name: Kalaris Therapeutics, Inc.
- filed_at: 2026-08-11T12:05:28+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1754068/000119312526343477/0001193125-26-343477-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1754068/000119312526343477/d114296d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-343477
- JSON: https://secwatch.observer/filing/0001193125-26-343477.json
- Plain text: https://secwatch.observer/filing/0001193125-26-343477.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.